Company intelligence / Profile preview

ATEM Capital

New York, New York, United Statesatemcap.com ↗

Ownership: Private
Employees: ~6
Development stage: Phase 1

Overview

ATEM Capital is an investment firm that focuses on life sciences companies. They have invested in companies like Triumvira Immunologics (developing T-Cell Antigen Coupler therapeutics), Amolyt Pharma (developing therapeutic peptides for rare endocrine diseases), Arpeggio Biosciences (developing drug discovery platform), and Deka Biosciences.

Therapeutic areas: OncologyInfectious DiseasesEndocrinologyImmunologyCardiovascularNeurologyWomen's Health
Modalities: Therapeutic peptidesCAR-TDNA storageAI drug discovery
Industry: Investors

Drug pipeline

1 asset

DK210

Phase 1

Indications: Cancer

Partnerships

OrbiMedPontifaxLeaps by BayerNorthpond Ventures

Beyond the preview

Go deeper on ATEM Capital.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATEM Capital.

Explore the full profile